Intranasal administration of the GHRP hexarelin accelerates growth in short children.

Laron Z, Frenkel J, Deghenghi R, Anin S, Klinger B, Silbergeld A

Clinical endocrinology1 Nov 1995Cited by 43 (Europe PMC)

PMID8548949DOI10.1111/j.1365-2265.1995.tb02929.xPepBankPUB-08548949

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialEfficacy outcome
In prepubertal short children, intranasal hexarelin raised IGF-I from 10.4 to 14.1 nmol/l.
In plain wordsIn short children before puberty, hexarelin nasal doses raised IGF-I levels.
Peptide
Hexarelin
Outcome
IncreaseIGF-I level
Study
n = 8
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
60 micrograms/kg thrice daily · intranasal · up to 8 monthsAs given in this study (human).
Measurements
IGF-I
10.4 nmol/l
baseline
IGF-I
14.1 nmol/l
after hexarelin
Source sentences
Summary
Hexarelin treatment stimulated insulin-like growth factor-I (IGF-I) secretion raising the level from 10.4 +/- 3.9 (SD) to 14.1 +/- 4.6 nmol/l (P < 0.004).
1 context sentence(design, population, supporting numbers)
Summary · context
Intranasal hexarelin was administered in a dose of 60 micrograms/kg thrice daily to 8 prepubertal short children aged 4-11.6 years for periods of up to 8 months.
Report a problemFND-0854894901
02HumanNon-randomized trialEfficacy outcome
In prepubertal short children, intranasal hexarelin increased mean linear growth velocity from 5.3 to 8.3 cm/year.
In plain wordsIn short children before puberty, hexarelin nasal doses sped up growth.
Peptide
Hexarelin
Outcome
IncreaseLinear growth velocity
Study
n = 8
Outcome group
Linear growth · Endocrine and hormones
Studied dose
60 micrograms/kg thrice daily · intranasal · up to 8 monthsAs given in this study (human).
Measurements
Linear growth velocity
5.3 cm/year
baseline
Linear growth velocity
8.3 cm/year
after hexarelin
Source sentences
Summary
The rise in IGF-I led to a significant increase in the mean (+/- SD) linear growth velocity from 5.3 +/- 0.8 to 8.3 +/- 1.7 cm/year (P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Intranasal hexarelin was administered in a dose of 60 micrograms/kg thrice daily to 8 prepubertal short children aged 4-11.6 years for periods of up to 8 months.
Report a problemFND-0854894902
03HumanNon-randomized trialEfficacy outcome
In prepubertal short children, intranasal hexarelin decreased skinfold thickness significantly.
In plain wordsIn short children before puberty, hexarelin nasal doses reduced skinfold thickness.
Peptide
Hexarelin
Outcome
DecreaseSkinfold thickness
Study
n = 8
Outcome group
Body weight · Metabolic and weight
Studied dose
60 micrograms/kg thrice daily · intranasal · up to 8 monthsAs given in this study (human).
Source sentences
Summary
There was also a significant decrease in skinfold thickness despite increase in body weight and an increase in head circumference.
1 context sentence(design, population, supporting numbers)
Summary · context
Intranasal hexarelin was administered in a dose of 60 micrograms/kg thrice daily to 8 prepubertal short children aged 4-11.6 years for periods of up to 8 months.
Report a problemFND-0854894903
04HumanNon-randomized trialEfficacy outcome
In prepubertal short children, body weight increased during intranasal hexarelin treatment.
In plain wordsIn short children before puberty, body weight went up during hexarelin nasal treatment.
Peptide
Hexarelin
Outcome
IncreaseBody weight
Study
n = 8
Outcome group
Body weight · Metabolic and weight
Studied dose
60 micrograms/kg thrice daily · intranasal · up to 8 monthsAs given in this study (human).
Source sentences
Summary
There was also a significant decrease in skinfold thickness despite increase in body weight and an increase in head circumference.
1 context sentence(design, population, supporting numbers)
Summary · context
Intranasal hexarelin was administered in a dose of 60 micrograms/kg thrice daily to 8 prepubertal short children aged 4-11.6 years for periods of up to 8 months.
Report a problemFND-0854894904
05HumanNon-randomized trialEfficacy outcome
In prepubertal short children, head circumference increased during intranasal hexarelin treatment.
In plain wordsIn short children before puberty, head circumference grew during hexarelin nasal treatment.
Peptide
Hexarelin
Outcome
IncreaseHead circumference
Study
n = 8
Outcome group
Linear growth · Endocrine and hormones
Studied dose
60 micrograms/kg thrice daily · intranasal · up to 8 monthsAs given in this study (human).
Source sentences
Summary
There was also a significant decrease in skinfold thickness despite increase in body weight and an increase in head circumference.
1 context sentence(design, population, supporting numbers)
Summary · context
Intranasal hexarelin was administered in a dose of 60 micrograms/kg thrice daily to 8 prepubertal short children aged 4-11.6 years for periods of up to 8 months.
Report a problemFND-0854894905
06HumanNon-randomized trialEfficacy outcome
In prepubertal short children, intranasal hexarelin raised serum phosphate from 1.5 to 1.8 mmol/l.
In plain wordsIn short children before puberty, hexarelin nasal doses raised blood phosphate.
Peptide
Hexarelin
Outcome
IncreaseSerum phosphate
Study
n = 8
Outcome group
Bone and joint · Musculoskeletal
Studied dose
60 micrograms/kg thrice daily · intranasal · up to 8 monthsAs given in this study (human).
Measurements
Serum phosphate
1.5 mmol/l
baseline
Serum phosphate
1.8 mmol/l
after hexarelin
Source sentences
Summary
Additional findings were a rise in serum phosphate from 1.5 +/- 0.1 to 1.8 +/- 0.1 mmol/l (P < 0.004) and of alkaline phosphatase from 219 +/- 74 to 261 +/- 75 U/l (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Intranasal hexarelin was administered in a dose of 60 micrograms/kg thrice daily to 8 prepubertal short children aged 4-11.6 years for periods of up to 8 months.
Report a problemFND-0854894906
07HumanNon-randomized trialEfficacy outcome
In prepubertal short children, intranasal hexarelin raised alkaline phosphatase from 219 to 261 U/l.
In plain wordsIn short children before puberty, hexarelin nasal doses raised blood alkaline phosphatase.
Peptide
Hexarelin
Outcome
IncreaseSerum alkaline phosphatase
Study
n = 8
Outcome group
Bone and joint · Musculoskeletal
Studied dose
60 micrograms/kg thrice daily · intranasal · up to 8 monthsAs given in this study (human).
Measurements
Alkaline phosphatase
219 U/l
baseline
Alkaline phosphatase
261 U/l
after hexarelin
Source sentences
Summary
Additional findings were a rise in serum phosphate from 1.5 +/- 0.1 to 1.8 +/- 0.1 mmol/l (P < 0.004) and of alkaline phosphatase from 219 +/- 74 to 261 +/- 75 U/l (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Intranasal hexarelin was administered in a dose of 60 micrograms/kg thrice daily to 8 prepubertal short children aged 4-11.6 years for periods of up to 8 months.
Report a problemFND-0854894907

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.